Citations (0)
Keep up to date with the latest research on this topic with citation updates for this article.
Future Oncology
Volume 18, 2022 - Issue 31
Clinical Trial Protocol
EPIK-O/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study)
Panagiotis A Konstantinopoulos1 Dana-Farber Cancer Institute, Boston, MA02215, USACorrespondence[email protected]
https://orcid.org/0000-0002-1032-1479View further author information
https://orcid.org/0000-0002-1032-1479View further author information, , , Michael Friedlander4 Department of Medical Oncology, Prince of Wales Hospital & Prince of Wales Clinical School, University of New South Wales, Sydney, 2031, Australiahttps://orcid.org/0000-0003-3090-795XView further author information
https://orcid.org/0000-0003-3090-795XView further author information, Rosalind Glasspool5 Beatson West of Scotland Cancer Centre & University of Glasgow, Glasgow, G12, UKhttps://orcid.org/0000-0002-5000-1680View further author information
https://orcid.org/0000-0002-5000-1680View further author information, Domenica Lorusso6 Fondazione Policlinico Universitario A Gemelli IRCCS & Catholic University of Sacred Heart, Rome, 00168, Italyhttps://orcid.org/0000-0003-0981-0598View further author information
https://orcid.org/0000-0003-0981-0598View further author information, Christian Marth7 Medizinische Universität Innsbruck, Innsbruck, 6020, Austriahttps://orcid.org/0000-0002-8965-9981View further author information
https://orcid.org/0000-0002-8965-9981View further author information, , Jae-Weon Kim9 Seoul National University, Seoul, 08826, South Koreahttps://orcid.org/0000-0003-1835-9436View further author information
https://orcid.org/0000-0003-1835-9436View further author information, , , , & Ursula A Matulonis1 Dana-Farber Cancer Institute, Boston, MA02215, USAhttps://orcid.org/0000-0002-3103-6992View further author information
https://orcid.org/0000-0002-3103-6992View further author information show all